Overview

Study of VX-770 and Rifampin in Healthy Male Subjects

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the effects of multiple doses of rifampin on the single-dose pharmacokinetics of VX 770.
Phase:
Phase 1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Rifampin